Debasis Bagchi
Biographic Data
| ID | 5505764 |
|---|---|
| NAME | Debasis Bagchi |
| GIVEN NAMES | Debasis |
| FAMILY NAME | Bagchi |
| SIGNATURE | BAGCHI D |
| AFFILIATIONS | Texas Southern University |
| ORCID | 0000-0001-9478-6427 |
| VERIFIED | Yes |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 2 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2021 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
The Emerging Crisis in Non-Prescribed Ketamine Use
BACKGROUND: Since 2000, rates of suicide and opioid overdose have sharply increased. Approximately one-third of individuals with major depressive disorder (MDD) experience treatment-resistant depression (TRD), highlighting the urgent need for novel therapeutic approaches. OBJECTIVE: This review synthesizes pivotal preclinical and clinical findings on low-dose ketamine's rapid antidepressant effects and examines proposed mechanisms underlying its …
Reward Deficiency Syndrome (RDS)
Alcohol and other substance use disorders share comorbidity with other RDS disorders, i.e., a reduction in dopamine signaling within the reward pathway. RDS is a term that connects addictive, obsessive, compulsive, and impulsive behavioral disorders. An estimated 2 million individuals in the United States have opioid use disorder related to prescription opioids. It is estimated that the overall cost of the illegal and legally prescribed opioid cr…
No prominent works on this page.
Reward Deficiency Syndrome (RDS)
Alcohol and other substance use disorders share comorbidity with other RDS disorders, i.e., a reduction in dopamine signaling within the reward pathway. RDS is a term that connects addictive, obsessive, compulsive, and impulsive behavioral disorders. An estimated 2 million individuals in the United States have opioid use disorder related to prescription opioids. It is estimated that the overall cost of the illegal and legally prescribed opioid cr…
The Emerging Crisis in Non-Prescribed Ketamine Use
BACKGROUND: Since 2000, rates of suicide and opioid overdose have sharply increased. Approximately one-third of individuals with major depressive disorder (MDD) experience treatment-resistant depression (TRD), highlighting the urgent need for novel therapeutic approaches. OBJECTIVE: This review synthesizes pivotal preclinical and clinical findings on low-dose ketamine's rapid antidepressant effects and examines proposed mechanisms underlying its …
Addiction (1 work) · Attention Deficit Hyperactivity Disorder (1 work) · Dopamine (1 work) · Dopaminergic (1 work) · Drug (1 work) · Escapism (1 work) · Forensic Toxicology and Drug Analysis (1 work) · Internal Medicine (1 work) · Ketamine (1 work) · Medicine (1 work)